Current Report Filing (8-k)
December 31 2018 - 7:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 27, 2018
HARROW
HEALTH, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-35814
|
|
45-0567010
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
12264
El Camino Real, Suite 350
|
|
|
San
Diego, CA
|
|
92130
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(858) 704-4040
Imprimis
Pharmaceuticals, Inc.
|
(Former
name or former address if changed since last report.)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.03 Amendments to Articles of Incorporation or Bylaws: Change in Fiscal Year.
Name
Change
On
December 27, 2018, Harrow Health, Inc. (formerly, Imprimis Pharmaceuticals, Inc.) (the “Company”) amended its restated
certificate of incorporation (“Amendment”) to change its corporate name from “Imprimis Pharmaceuticals, Inc.”
to “Harrow Health, Inc.”
The
name change was previously approved by the Board of Directors. The shareholders, under Delaware General Corporation Law, were
not required to approve the name change.
The
stockholders do not need to take any action as a result of the name change, including that there is no need to exchange their
certificates representing their shares of common stock. The current stock certificate will continue to represent their ownership
interest in the Company. Stockholders, however, may return their certificates to the transfer agent for the Company and obtain
an updated certificate.
A
copy of the Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K.
The
press release relating to the name change being completed and reflected on The NASDAQ Capital Market is being furnished as Exhibit
99.1 to this Current Report on Form 8-K.
Item
8.01 Other Events
Symbol
Change
The
trading symbol reflecting the new name for the company, for the common stock of the Company, on The NASDAQ Capital Market is HROW.
Item
9.01. Financial Statements and Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Imprimis
Pharmaceuticals, Inc.
|
|
|
Date:
December 31, 2018
|
By:
|
/s/
Andrew R. Boll
|
|
Name:
|
Andrew
R. Boll
|
|
Title:
|
Chief
Financial Officer
|
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Apr 2024 to May 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From May 2023 to May 2024